(Q79874752)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16832384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16832384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

Bastide C

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16832384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Kuefer R

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16832384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Loeffler M

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16832384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

de Petriconi R

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16832384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Gschwend J

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16832384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Hautmann R

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16832384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

11 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16832384%20AND%20SRC:MED&resulttype=core&format=json

Prostate Cancer and Prostatic Diseases

26 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16832384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16832384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16832384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

239-244

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16832384%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500892

26 December 2019

exact match

0 references

cites work

Prediction of capsular perforation and seminal vesicle invasion in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Pretreatment predictors of time to cancer specific death after prostate specific antigen failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Radical retropubic prostatectomy: morbidity and urinary continence in 418 consecutive cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Early post-operative morbidity of total prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Prospective assessment of incontinence after radical retropubic prostatectomy: objective and subjective analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Biochemical disease-free survival in patients with a high prostate-specific antigen level (20-100 ng/mL) and clinically localized prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500892

7 January 2021

Identifiers

DOI

10.1038/SJ.PCAN.4500892

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16832384%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference